1. Pharmacokinetics and pharmacodynamics of dovitinib from 5 clinical trials and the introduction to the intermittent dosing schedule;Wang;J Clin Pharmacol
2. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins;Deprimo;J Transl Med,2007
3. Shi M 2008
4. The pharmacodynamic effect of TKI258 on plasma biomarkers of angiogenesis in patients with AML and advanced melanoma;Shi;ASCO Meeting Abstracts,2008
5. Wang X Anak O Saro J et al. Population PK modeling/simulation to select a dosing schedule in phase II/III trials for a novel TKI agent with time-dependent and nonlinear PK. Paper presented at: Population Approach Group in Europe Annual Meeting; June 23-26